In important tests against a difficult-to-treat strain of human colon cancer cells (HCT116), scientists evaluated the performance of concentrated amounts of company’s newest anticancer compounds. Researchers observed a 50% or greater cancer cell kill rate using these patented compounds, reporting excellent success in the company’s second Phase tests where they have employed new, synthetic bis-acridines for the first time.
Greg Wujek, president and CEO of PhytoMedical, said: “Based on encouraging outcomes from early Phase one research into our first-generation anticancer compounds, we immediately bolstered our efforts and initiated tests of our next-generation compounds. These Phase two tests were specifically designed to target difficult-to-treat strains of human cancer cells, and the resulting outcomes have been very favorable.”